On Monday, Ciena Corporation (NYSE:CIEN)’s shares declined -1.96% to $24.95.
Ciena® Corporation (CIEN), the network specialist, declared the successful completion of its acquisition of Cyan, Inc., a leading provider of next-generation software and platforms to enable open, agile and scalable software-defined netoperates, following the terms of the acquisition agreement.
Blue Planet Division
Ciena is committed to leading the industry into a new era of truly open, software-defined, multi-vendor netoperates. Accordingly, in conjunction with recently declarement, Ciena is unifying the software activities of both companies under a single brand and set of resources known as the Blue Planet division. The division, which comprises Ciena’s former Agility business, will focus on assisting customers automate services – from creation to orchestration to delivery – across both physical and virtual domains, in order to drive greater competitive advantage, create new revenue opportunities, and lower costs associated with hardware and operations.
Ciena Corporation provides equipment, software, and services that support the transport, switching, aggregation, service delivery, and administration of voice, video, and data traffic on communications netoperates worldwide. The companys Converged Packet Optical segment offers networking solutions optimized for the convergence of coherent optical transport, OTN switching, and packet switching.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s shares gained 0.62% to $147.17.
BioMarin Pharmaceutical Inc. (BMRN) declared financial results for the second quarter ended June 30, 2015. Non-GAAP net loss was $5.4 million for the second quarter of 2015, contrast to non-GAAP net income of $10.1 million for the second quarter of 2014. GAAP net loss was $82.0 million, or ($0.51) per basic and diluted share for the second quarter of 2015, contrast to GAAP net loss of $33.5 million, or ($0.23) per basic and diluted share for the second quarter of 2014. The raised non-GAAP net loss and GAAP net loss for the second quarter of 2015 contrast to the second quarter of 2014 was primarily due to raised operating expenses, partially offset by raised revenues due to the strong commercial launch of Vimizim.
Total BioMarin Revenue was $250.5 million for the second quarter of 2015, an enhance of 31% contrast to the second quarter of 2014. This enhance was driven by solid growth across all BioMarin products counting Kuvan, Naglazyme and Vimizim. Sales of Vimizim, now in its fifth full quarter of sales since being approved in early 2014, were recorded in 30 countries in the second quarter and totaled $53.9 million. Naglazyme Net Product Revenue in the second quarter benefitted from a large order in Latin America, compriseent with historically uneven sales of the product in that region. This trend is not predictable to continue for the remainder of 2015. Kuvan Net Product Revenue in the second quarter raised 28% to $60.1 million driven primarily by patient count enhances and high rates of compliance. On a constant currency basis, Total BioMarin Revenue in the second quarter would have been about $260.5 million.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products comprise Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease.
At the end of Monday s trade, Avnet, Inc. (NYSE:AVT)‘s shares dipped -0.81% to $41.39.
Avnet Electronics Marketing, an operating group of Avnet, Inc. (AVT), released the new Zynq®-7000 All Programmable SoC/Analog Devices Intelligent Drives Kit II. The kit is designed to provide a flexible platform for motor control and industrial networking development in sectors counting industrial automation, smart energy, medical and embedded systems. This evolution of the original Zynq-7000 All Programmable SoC/Analog Devices Intelligent Drives Kit offers improved performance features counting greater precision data converters from Analog Devices, higher frequency direct drive of the H-bridge power stages and simultaneous drive of two motors, counting bipolar steppers or BLDC with electronic brake.
Avnet, Inc., together with its auxiliaries, distributes electronic components, enterprise computer and storage products, IT solutions and services, and embedded subsystems in the Americas, Europe, the Middle East, Africa, and the Asia/Pacific. It operates through two segments, Electronics Marketing (EM) and Technology Solutions (TS).
Energous Corp (NASDAQ:WATT), ended its Monday’s trading session with -4.28% loss, and closed at $6.94.
Energous Corporation (WATT), the developer of WattUp™, a revolutionary wire-free charging technology for mobile devices that provides power at a distance, has been invited to present at the Oppenheimer 18th Annual Technology, Internet & Communications Conference. The conference is being held on August 11-12, 2015 at The Four Seasons Hotel in Boston, MA.
Energous administration is planned to present on Tuesday, August 11, 2015 at 11:45 am ET in the Phillips Room. They will also be holding one-on-one meetings throughout the day.
Energous Corporation, a technology company, engages in the development of a wire-free charging system. Its technology could enable wire-free charging of electronic devices at a distance. The company is developing WattUp, a wire-free charging technology that transforms the charging and powering of electronic devices at home, in addition to in the office and car.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
